×
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
QQQ   309.10 (+3.26%)
AAPL   149.64 (+4.08%)
MSFT   273.24 (+2.76%)
FB   195.13 (+1.83%)
GOOGL   2,246.33 (+4.20%)
AMZN   2,302.93 (+3.66%)
TSLA   759.63 (+7.33%)
NVDA   188.11 (+5.38%)
BABA   93.41 (-1.13%)
NIO   16.57 (+3.37%)
AMD   102.26 (+3.55%)
CGC   4.88 (-12.07%)
MU   73.32 (+3.85%)
T   21.29 (-0.14%)
GE   78.76 (+2.27%)
F   13.63 (+3.89%)
DIS   109.32 (+3.51%)
AMC   14.43 (+17.99%)
PFE   53.91 (-0.15%)
PYPL   85.21 (+5.96%)
NFLX   195.19 (+1.98%)
NASDAQ:NVAX

Novavax (NVAX) Stock Forecast, Price & News

$55.29
+8.22 (+17.46%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$46.19
$56.52
50-Day Range
$42.92
$83.80
52-Week Range
$41.33
$277.80
Volume
7.47 million shs
Average Volume
5.13 million shs
Market Capitalization
$4.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.59
30 days | 90 days | 365 days | Advanced Chart
Receive NVAX News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

Novavax logo

About Novavax

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NVAX
CUSIP
67000210
Employees
1,541
Year Founded
1987

Sales & Book Value

Annual Sales
$1.15 billion
Book Value
$0.84 per share

Profitability

Net Income
$-1.74 billion
Pretax Margin
-91.86%

Debt

Price-To-Earnings

Miscellaneous

Free Float
76,494,000
Market Cap
$4.32 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/09/2022
Today
5/27/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

1.98 out of 5 stars

Medical Sector

620th out of 1,424 stocks

Biological Products, Except Diagnostic Industry

99th out of 209 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Novavax (NASDAQ:NVAX) Frequently Asked Questions

Is Novavax a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Novavax stock.
View analyst ratings for Novavax
or view top-rated stocks.

When is Novavax's next earnings date?

Novavax is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Novavax
.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) released its earnings results on Monday, May, 9th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.33 by $0.77. The biopharmaceutical company earned $703.97 million during the quarter, compared to analyst estimates of $845.20 million. Novavax had a negative net margin of 93.91% and a negative trailing twelve-month return on equity of 572.54%. The business's revenue for the quarter was up 57.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($3.05) earnings per share.
View Novavax's earnings history
.

When did Novavax's stock split? How did Novavax's stock split work?

Shares of Novavax reverse split on the morning of Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax issued an update on its FY 2022 earnings guidance on Monday, May, 23rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $4.00 billion-$5.00 billion, compared to the consensus revenue estimate of $4.49 billion.

What price target have analysts set for NVAX?

8 brokers have issued 12 month target prices for Novavax's stock. Their forecasts range from $35.00 to $209.00. On average, they expect Novavax's share price to reach $164.86 in the next year. This suggests a possible upside of 198.2% from the stock's current price.
View analysts' price targets for Novavax
or view top-rated stocks among Wall Street analysts.

Who are Novavax's key executives?
Novavax's management team includes the following people:
  • Mr. Stanley Charles Erck, Pres, CEO & Director (Age 74, Pay $1.26M)
  • Mr. John A. Herrmann III, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 56, Pay $655.95k) (LinkedIn Profile)
  • Mr. John Joseph Trizzino B.S., M.B.A., Exec. VP and Chief Bus. & Commercial Officer (Age 62, Pay $676.83k)
  • Dr. Gregory M. Glenn, Pres of R&D (Age 68, Pay $857.42k) (LinkedIn Profile)
  • Mr. James Patrick Kelly C.F.A., Exec. VP, CFO & Treasurer (Age 56)
  • Mr. Richard P. Crowley, Exec. VP & COO (Age 65)
  • Dr. Gale E. Smith, Sr. VP of Discovery & Pre-Clinical Research and Chief Scientist (Age 72)
  • Mr. Biegie Lee, Sr. VP & Chief Information Officer
  • Ms. Silvia Taylor M.B.A., MBA, Sr. VP of Global Corp. Affairs & Investor Relations
  • Mr. Troy Morgan Esq., Sr. VP & Chief Compliance Officer (Age 51)
What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax CEO Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among Novavax's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Palo Alto Networks (PANW), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Who are Novavax's major shareholders?

Novavax's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.92%), State Street Corp (3.19%), Citigroup Inc. (0.00%), Jane Street Group LLC (0.00%), Coatue Management LLC (1.13%) and JPMorgan Chase & Co. (0.00%). Company insiders that own Novavax stock include David M Mott, Gary C Evans, Gregory M Glenn, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr, Rachel K King and Stanley C Erck.
View institutional ownership trends for Novavax
.

Which institutional investors are selling Novavax stock?

NVAX stock was sold by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Capital World Investors, Jane Street Group LLC, PEAK6 Investments LLC, Graham Capital Management L.P., Simplex Trading LLC, First Trust Advisors LP, and Group One Trading L.P.. Company insiders that have sold Novavax company stock in the last year include David M Mott, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, and Stanley C Erck.
View insider buying and selling activity for Novavax
or view top insider-selling stocks.

Which institutional investors are buying Novavax stock?

NVAX stock was bought by a variety of institutional investors in the last quarter, including Coatue Management LLC, State Street Corp, Citigroup Inc., Goldman Sachs Group Inc., Capital Fund Management S.A., Qube Research & Technologies Ltd, International Biotechnology Trust PLC, and JPMorgan Chase & Co.. Company insiders that have bought Novavax stock in the last two years include James F Young, and Rachel K King.
View insider buying and selling activity for Novavax
or or view top insider-buying stocks.

How do I buy shares of Novavax?

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $55.29.

How much money does Novavax make?

Novavax has a market capitalization of $4.32 billion and generates $1.15 billion in revenue each year. The biopharmaceutical company earns $-1.74 billion in net income (profit) each year or ($17.680010) on an earnings per share basis.

How many employees does Novavax have?

Novavax employs 1,541 workers across the globe.

When was Novavax founded?

Novavax was founded in 1987.

What is Novavax's official website?

The official website for Novavax is www.novavax.com.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at [email protected], or via fax at 240-268-2100.

This page was last updated on 5/27/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.